Parker Waichman LLP, a national law firm that advocates for the rights of victims harmed by defective drugs, has filed a lawsuit in Superior Court of New Jersey, Atlantic County Law Division on behalf of a woman who allegedly suffered a right femur fracture due to Fosamax. The lawsuit names Merck Sharp & Dohme Corp., and Merck & Co., as defendants.
The lawsuit says that the Rhode Island plaintiff used Fosamax as prescribed for years, and as a direct result of Fosamax, she suffered a right subtrochanteric femur fracture. The plaintiff says that if the defendants had adequately warned of the risks of the drug, specifically that the long-term use of Fosamax can make bones more susceptible to fracture, she would not have taken Fosamax. The lawsuit says that Merck knew or should have known about the risks that long-term use of Fosamax poses, and that instead of warning the public about those risks, Merck promoted Fosamax as an effective treatment to reduce the risks of bone fractures due to osteoporosis in post-menopausal women.
The lawsuit alleges that the plaintiff suffered serious consequences from using Fosamax, including severe physical and mental pain and suffering, permanent injury, emotional distress, economic loss due to medical expenses and living related expenses due to a new lifestyle.